A PHASE II OPEN-LABEL MULTI-COHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS

Brief description of study

This is a Phase II, open-label, multicohort, multicenter study in patients with unresectable, locally advanced, or metastatic HCC who have Child-Pugh B7 or B8 liver cirrhosis who have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety and efficacy of atezolizumab plus bevacizumab or atezolizumab monotherapy in this population.


Clinical Study Identifier: s23-00394
ClinicalTrials.gov Identifier: NCT06096779
Principal Investigator: Kristen Spencer.
Other Investigators: Jennifer Wu, Daniel J Becker, Marta Wioleta Wronska, Jennifer Chuy, Keriann M Scavone, Nina Beri, Paul E. Oberstein, Michael Shusterman, Rafael Winograd, Shun Yu, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.